Glucagon-like peptide 1 (GLP-1) receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have increased in popularity within the recent years both as diabetes and weight loss medications. This evidence concerns the gene GCG and diabetes mellitus.